1-((2S,5R)-5-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one

Ritlecitinib, a dual JAK3/TEC inhibitor, was granted FDA breakthrough status for treating alopecia areata (autoimmune-induced hair loss) in September 2018. Promising phase 3 trial results in alopecia areata were reported by Pfizer in August 2021, placing it in competition with Lilly/Incyte's Olumiant. It is also used in clinical studies to treat vitiligo, rheumatoid arthritis, Crohn's disease, and ulcerative colitis. Ritlecitinib achieved high JAK3 selectivity via covalent interaction with a unique cysteine residue (Cys909) in the catalytic domain.

About Jianfeng Chemical

Founded in 2011, our company is a leading research-driven pharmaceutical company, mainly manufactures pharmaceutical APIs and intermediates. Owing to the good quality and competitive price, we have a very good reputation in China's pharmaceutical circles.

How To Cooperate With Us?

--Contact us via Email.

--Leave us a message about the products you want.

--Description of order quantity.

--Please tell us your shipping address.

--The sales manager gives you a quote and sends you a contract.

--Delivery the same day after payment.

Hot Tags: 1-((2s,5r)-5-((7h-pyrrolo[2,3-d]pyrimidin-4-yl)amino)-2-methylpiperidin-1-yl)prop-2-en-1-one, China, suppliers, manufacturers, factory, wholesale, buy, bulk, price, for sale, in stock, Loteprednol Powder, Medicine Grade Flurbiprofen Powder, Pharmaceutical Raw Materials API, API Nepafenac Powder, Pure Lidocaine Powder, Bisoprolol Fumarate Powder